Anavex Life Sciences Corp (AVXL)

[end2war]

Of course the drug clearly appears to work, but still using the exact same measure and zero drug PK exposure, 38.5% of placebo patients are Responders and this is quite high. Higher I would think than most of us would have expected especially given the more stringent endpoint measurement.

One thought that I have about the high false positives is that it shows strong support from the caregivers/family which think their patient is improving, and that bodes well for A2-73 to get support if an application is filed with the agencies. Having good support for the drug that has some subjectivity will be a positive force for approval, and I think the parents will be influential.

Another thing about his false positive score is that there will be some key placebos to watch in the 48-week extension study. How do the false positives do with the real drug over 48 weeks; and how do the placebos do that were rated non-responders? Do the switch to clear responders with big effects?